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Background: Classification of lung carcinoids into typical and atypical is a diagnostic challenge since no immunohistochemical
tools are available to support pathologists in distinguishing between the two subtypes. A differential diagnosis is essential for
clinicians to correctly discuss therapy, prognosis and follow-up with patients. Indeed, the distinction between the two typical and
atypical subtypes on biopsies/cytological specimens is still unfeasible and sometimes limited also after radical surgeries. By
comparing the gene expression profile of typical (TC) and atypical carcinoids (AC), we intended to find genes specifically
expressed in one of the two subtypes that could be used as diagnostic markers.
Methods: Expression profiling, with Affymetrix arrays, was performed on six typical and seven atypical samples. Data were
validated on an independent cohort of 29 tumours, by means of quantitative PCR and immunohistochemistry (IHC).
Results: High-throughput gene expression profiling was successfully used to identify a gene signature specific for atypical lung
carcinoids. Among the 273 upregulated genes in the atypical vs typical subtype, GC (vitamin D-binding protein) and CEACAM1
(carcinoembryonic antigen family member) emerged as potent diagnostic markers. Quantitative PCR and IHC on a validation set
of 17 ACs and 12 TCs confirmed their reproducibility and feasibility.
Conclusions: GC and CEACAM1 can distinguish between TC and AC, defining an IHC assay potentially useful for routine
cytological and histochemical diagnostic procedures. The high sensitivity and reproducibility of this new diagnostic algorithm
strongly support a further validation on a wider sample size.
Gene expression microarrays can be used to identify signatures
specific for tumour subtypes, allowing the classification into categories
with a potential impact on clinical practice. In lung cancer, expression
profiling unravelled interesting aspects regarding early diagnosis
(Spira et al, 2007; Beane et al, 2008), prognosis (Bianchi et al,
2007), and treatment (Gyorffy et al, 2006; Gemma et al, 2006).
Lung carcinoids are rare malignant neuroendocrine tumours,
accounting for the 1.2% of all lung cancer cases (SEER Research
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Data, 1973–2004). According to the World Health Organization
(WHO) classification, lung neuroendocrine tumours comprise four
different tumour types: the low-grade typical carcinoid (TC), the
intermediate-grade atypical carcinoid (AC), the high-grade large-cell
neuroendocrine carcinoma (LCNEC) and small-cell lung cancer
(SCLC) (Arrigoni et al, 1972; Travis et al, 1998; Scott, 2003). The
subclassification of lung carcinoid tumours into typical and atypical
is of clinical importance. Typical carcinoid and AC show a different
biological behaviour, accounting for the different prognosis: the
5-year survival rate is 40–69% for ACs and 87–100% for TCs (Scott,
2003). As a consequence, distinguishing AC from TC is necessary to
correctly discuss patient’s prognosis and follow-up, as well as to
select patients suitable for clinical trials to test new drugs in adjuvant
settings. Moreover, discovering a tool that allows a differential
diagnosis between TC and AC in pre-operative cytological or
histological specimens could be extremely useful for an individual
clinical decision-making, whenever surgery is a high-risk procedure.
Histologically, it is possible to distinguish between TC and AC
according to the number of mitosis and the presence of necrosis:
TC is characterised byo2 mitoses per 2mm2 (10 HPF) with no
necrosis, while AC is defined by a number of mitoses between 2
and 10 per 2mm2 and/or coagulative necrosis. Pathologists
referent for these malignances (Scott, 2003; Skov et al, 2008)
acknowledge such diagnostic parameters as very difficult to assess,
because depending on the size and quality of the specimens.
Furthermore, prolonged or inadequate fixation, thick sections,
suboptimal staining, or the presence of extensive necrosis, fibrous
or inflammatory stroma, and crush artefacts can considerably
hamper the evaluation, clearly suggesting that the definition of
easily reproducible diagnostic tools is a major clinical need.
The identification of genes differently expressed in TC and AC
may be able to identify an AC-specific signature, which, aside from
revealing new insights into the nature of these tumours, could
display a potential impact on diagnosis.
MATERIALS AND METHODS
Affymetrix microarray. The test set was composed by seven TC
and nine AC (diagnosis from the Division of Pathology at the
European Institute of Oncology). All the patients not chemo-radio
naı¨ve and with a second tumour were excluded from the study. A
written informed consent for research use of biological samples
was obtained from all the patients.
RNA was extracted from frozen samples with high tumour
cellularity (475%). RNA extraction was performed, using the
Illustra RNAspin mini kit (GE Healthcare, Little Chalfont, UK)
and following the manufacturer’s indications. Tumour sections
were prepared and stored in RNAspin Lysis solution at  80 1C
until extraction. RNA integrity was assessed by using an Agilent
2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Labelled
fragmented cRNA (12 mg) was hybridised to oligonucleotide probes
on Affymetrix HG-U133 Plus 2.0 arrays containing 54 675 sets of
oligonucleotide probesets, which correspond to E30 000 unique
human genes. Scanned GeneChip images were processed using the
Affymetrix GCOS 1.4 software (Affymetrix, Santa Clara, CA, USA)
to obtain an intensity value. Probeset intensities were imported in
Partek GS v6.5 (Partek Incorporated, St Louis, MO, USA), and
processed using the robust multi-array analysis (RMA) algorithm
for background adjustment, normalisation, and log2 transforma-
tion of perfect match (PM) values (Irizarry et al, 2006). Data were
normalised to the median of all samples. We build an ANOVA
one-way model with the two main categories comparing TC vs AC.
We selected high confidence genes with a P-value of o0.01
(ANOVA one-way, Bonferroni Step-Up multiple-test correction)
and fold change Xþ 2 or p 2. We clustered the significant
genes (hierarchical clustering, euclidean distances, average linkage
method) and plotted as a heatmap. Microarrays were quality
checked for potential technical artefacts and three outliers were
removed. More in detail, in order to improve classifiers prediction
accuracy we used principal component analysis (PCA) as
implemented in Partek GS. We detected 3 outliers (1 TC and 2
ACs) and removed them from further analysis (leaving a total of 13
samples, 6 TCs and 7 ACs).
The data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus (Edgar et al, 2002) and are
accessible through GEO Series accession number GSE35679
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35679).
Diagnostic markers selection. Among 273 upregulated genes in
ACs vs TCs, the top 10 scoring the highest fold changes (ranging
from 38.766 to 534.063, ACs vs TCs) were selected and the absolute
expression values for each sample were considered. A comparison
between atypical vs typical tumour values allowed the selection of
two markers (GC and CEACAM1) clearly discriminating the two
subtypes (Supplementary Table 1).
Quantitative PCR and immunohistochemistry. qRT-PCR was
carried out on the ABI/Prism 7900 HT Sequence Detector System
(Applied Biosystems, Foster City, CA, USA), using a pre-PCR step
of 10min at 94.5 1C, followed by 40 cycles of 30 s at 97 1C and 60 s
at 59.7 1C. TaqMan Arrays’ 384 wells are pre-loaded with TaqMan
Gene Expression Assays. Each TaqMan Array evaluates two cDNA
samples in triplicate generated in a reverse transcription step using
random primers. Selected Taqman assays for GC and CEACAM1
were GC-Hs00167096_m1 and CEACAM1-Hs00266109_m1 by
Applied Biosystems. Values relative to the 18s housekeeping gene
were used to normalise the data. A mix composed of RNA samples,
obtained from the five typical tumours studied in the expression
profiling experiment, was used as a calibrator. For each reaction,
100 ng of cDNA was added to 100 ml of reaction mix containing
50 ml of TaqMan PCR Mastermix 2x No UNG (Applied
Biosystems) and loaded into each sample-loading port of 384-well
TaqMan Low Density Arrays.
Immunohistochemistry (IHC) was performed according to the
standard operating procedures applied at the Division of
Pathology. Anti-GC and anti-CEACAM1 antibodies were used
according to the following specifications: anti-GC dilution 1 : 200
(cod. HPA001526; Sigma-Aldrich Corp., St Louis, MO, USA);
anti-CEACAM1 dilution 1 : 100 (cod. ab49510-100, clone 29H2;
Abcam, Cambridge, UK).
Tumour samples. Frozen carcinoid samples were specifically
collected at the European Institute of Oncology for this project
starting from 2007. FFPE carcinoid samples were retrieved from
the institute archive. As for the 16 tumour samples constituting the
test set, all the 29 samples selected for the validation set were
chemo-radio naı¨ve.
RESULTS
The Affymetrix microarray technology was chosen to generate
expression profiles from a total of 13 frozen samples (training set),
6 from typical and 7 from atypical surgically resected primary lung
carcinoids (Figure 1; Supplementary Table 2). As represented in
Supplementary Table 1, the derived expression profile revealed 584
differentially expressed genes, separating AC from TC. We initially
focused on the group of 273 upregulated transcripts, specifically
concentrating on those absolute expression values clearly differ-
entiating ACs from TCs. This lead to the identification of GC
(vitamin D-binding protein) and CEACAM1 (carcinoembryonic
antigen family member), which scored among the highest fold
changes (Material and methods; Supplementary Table 1). More
precisely, we selected GC because showing the highest differences
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in the expression levels, and CEACAM1 that has already been
described overexpressed in several tumour types (Beauchemin and
Arabzadeh, 2013). The significant differences among the two
tumour types prompted us to consider these two genes as interesting
candidates for the definition of a new diagnostic strategy.
To confirm the different GC and CEACAM1 levels in ACs vs
TCs, we checked for their expression by (i) quantitative PCR
(qRT-PCR) on an independent cohort of 12 patients (frozen
samples from 6 TCs and 6 ACs) and (ii) IHC on the same 12 plus
additional 17 tumours (FFPE samples from 17 TCs and 12 ACs),
defining a validation set of 29 samples in total. The features of
the patients and the tumours analysed are summarised in
Supplementary Table 3.
In parallel, we completed our analysis with an independent
review of the 29 cases constituting the validation set, performed by
two pathologists dedicated to thoracic malignancies. As a result,
and consistently with acknowledged diagnostic difficulties, the
classification of the analysed samples was revised (Table 1): four
cases of TCs (patients 2, 3, 4, and 21) were considered as ACs
whereas one previous AC (patient 7) was classified as TC. The
reasons for the change in the diagnosis consisted mainly in the
strict application of the parameters proposed by the WHO
classification. New 2- to 4-mm-thick routine histological sections
and consecutive Ki-67 stained sections consented to detect mitoses,
discriminating them from nuclear picnosis or from regressive
nuclear alterations related to apoptosis.
The results of qRT-PCR analysis recapitulated the new patholo-
gical assessment (Figure 2A vs B), identifying the 4 misdiagnosed
cases among the 12 analysed and detecting higher levels of both GC
and CEACAM1 in atypical tumours (Figure 2B). Similarly, IHC
evidenced that all tumours showing CEACAM1 expression were
ACs (Figure 3). For tumours not showing CEACAM1 IHC
staining, instead, GC expression became relevant: o20% GC
positivity was detected only in TCs. Samples with GC positivity up
to 40%, but with low expression levels (1þ ) were also detected
only in TCs. Conversely, samples showing GC positivity in420%
of cells with medium to high expression levels (2þ ; 3þ ) were
only ACs (Table 2). Strikingly, the analysis of immunohisto-
chemical levels confirmed all the five misdiagnoses evidenced in
the entire validation set, although the GC/CEACAM1 staining vs
the pathologic evaluation remained discordant in four cases
(18, 20, 22, and 24; Table 1). Of note, also the 13 initial cases
(Affymetrix microarray analysis) underwent the pathologist’s
re-evaluation, confirming the diagnoses of 6 TCs and 7 ACs.
On the basis of our data, we defined a new immunohisto-
chemical diagnostic algorithm, hypothesising that the availability
of these ancillary markers could have avoided the diagnostic
misinterpretation.
DISCUSSION
A differential diagnosis between TC and AC is relevant for
clinicians to correctly discuss prognosis and follow-up with
patients after surgery, as well as for surgical decision-making in
Atypical
Typical
Standardised intensity
–24 0 2.3
Figure 1. Hierarchical clustering of 584 differentially expressed genes in 13 lung carcinoid samples. Atypical samples are represented in the
upper part of the dendrogram and typical samples in the lower. Expression levels are expressed according to the standardised intensity indicated
in the scale at the bottom of the figure (higher levels in red and lower in blue).
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borderline cases and as a main inclusion criteria in experimental
studies of systemic treatment.
Differently from the classification of gastrointestinal carcinoids,
which has incorporated the Ki-67 index, pulmonary carcinoids
are subdivided into typical and atypical only on the base of
the mitotic count and/or the presence of necrosis. Recently, the
use of the Ki-67 index has been explored also for lung carcinoids
but, unfortunately, even if the two subtypes show different mean
Ki-67 values, the distribution of Ki-67 indices in the two groups
frequently overlaps, making this marker only partially useful for
differential diagnosis (Walts et al, 2012). Therefore, up to now, no
immunohistochemical tools are available to support pathologists in
distinguishing between TC and AC except those parameters
defined by the WHO classification, which are sometimes difficult
to interpret, especially in cases of poor quality or small quantities
of material.
We performed an Affymetrix microarray gene expression
profiling to identify a gene signature specific for atypical lung
carcinoids. Among the most overexpressed genes in AC vs TC, we
selected GC (vitamin D-binding protein or Graves Diseases
Susceptibility To-gene) and CEACAM1 (carcinoembryonic antigen
family member) that we validated by means of qRT-PCR and IHC
as new potential diagnostic markers. GC, the vitamin D-binding
protein (VDBT) has a relevant immunomodulatory function in the
lung and protein variations have been associated with airways
diseases, such as chronic obstructive pulmonary disease (COPD),
asthma, bronchiectasias, and lung cancer (Chishimba et al, 2010).
CEACAM1 encodes a member of the carcinoembryonic antigen
(CEA) gene family, which belongs to the immunoglobulin
superfamily. Being involved in intercellular and intracellular
signalling, CEACAM1 has a pleiotropic role in normal homeostasis
and tumour progression (Ergun et al, 2000; Beauchemin and
Arabzadeh, 2013). In particular, the expression of CEACAM1 in
the tumour microenvironment significantly contributes to angio-
genesis and tumour metastasis. A further contribution to tumour
progression derives from CEACAM1 involvement in immune
response: its expression on melanoma cells prevents attacks from
T and NK cells (Ortenberg et al, 2012). For these reasons, it is
considered as a promising therapeutic target, because inhibitory
antibodies targeting CEACAM1 could render tumour cells more
susceptible to the immune system attack. Moreover, because
overexpressed in several tumours, CEACAM1 could represent a
novel therapeutic target as well as a biomarker to monitor disease
progression. This concept could also apply to ACs, since our data
Table 1. Diagnoses of patients included into the validation set, according to routine evaluation, blind revision, and IHC markers
Patient Routine diagnosis Blind revision Markers CEACAM % cells (intensity) GC % cells (intensity)
1 Typical Typical Typical 0 10 (weak 1þ )
2 Typical Atypical Atypical 80 (intense 3þ ) 75 (intense 3þ )
3 Typical Atypical Atypical 75 (moderate 2þ ) 20 (intense 3þ )
4 Typical Atypical Atypical 75 (moderate 2þ ) 75 (intense 3þ )
5 Typical Typical Typical 0 0
6 Typical Typical Typical 0 20 (weak 1þ )
7 Atypical Typical Typical 0 10 (weak 1þ )
8 Atypical Atypical Atypical 0 80 (moderate 2þ )
9 Atypical Atypical Atypical 30 (intense 3þ ) 75 (intense 3þ )
10 Atypical Atypical Atypical 20 (weak 1þ ) 75 (moderate 2þ )
11 Atypical Atypical Atypical 75 (intense 3þ ) 30 (moderate 2þ )
12 Atypical Atypical Atypical 75 (moderate 2þ ) 60 (intense 3þ )
13 Atypical Atypical Atypical 0 40 (moderate 2þ )
14 Typical Typical Typical 0 10 (weak 1þ )
15 Typical Typical Typical 0 20 (moderate 2þ )
16 Typical Typical Typical 0 40 (weak 1þ )
17 Typical Typical Typical 0 0
18 Typical Typical ATYPICAL 10 (weak 1þ ) 40 (intense 3þ )
19 Typical Typical Typical 0 0
20 Typical Typical ATYPICAL 10 (weak 1þ ) 40 (intense 3þ )
21 Typical Atypical Atypical 20 (weak 1þ ) 40 (intense 3þ )
22 Typical Typical ATYPICAL 50 (moderate 2þ ) 40 (intense 3þ )
23 Typical Typical Typical 0 10 (weak 1þ )
24 Atypical Atypical TYPICAL 0 20 (moderate 2þ )
25 Atypical Atypical Atypical 0 25 (moderate 2þ )
26 Atypical Atypical Atypical 10 (weak 1þ ) 10 (intense 3þ )
27 Atypical Atypical Atypical 0 80 (weak 1þ )
28 Atypical Atypical Atypical 0 25 (moderate 2þ )
29 Typical Typical Typical 0 5 (weak 1þ )
Abbreviation: IHC¼ immunohistochemistry. Misdiagnosed samples are evidenced in grey. Discordances between pathological and immunohistochemical evaluations are indicated in capital
letters. Patients’ number corresponding to the 12 cases analysed also by qRT-PCR are in bold.
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indicate high CEACAM1 expression in this subtype. In terms of
correlation with the clinical outcome, a role for GC has not
definitely been addressed, while an association between CEACAM1
expression and negative prognosis has already been proposed.
Indeed, lung adenocarcinomas expressing CEACAM1 showed a
worst overall and disease-free survival compared with negative
tumours (Laack et al, 2002).
When GC and CEACAM1 are evaluated together, they proved
to be a potent tool able to discriminate ACs from TCs, resulting in
the definition of an IHC assay possibly suitable for routine
diagnostic procedures. On the basis of our data, we derived an
algorithm, represented in Table 2, with a sensitivity ranging from
80% for TC to 90% for AC, as determined in our sample of 29
carcinoid tumours and assuming the double blind revision as a
reference (Supplementary Table 4).
The development of this new tool is of great importance,
considering that the distinction between the two tumour subtypes
on biopsies/cytological specimens is still unfeasible and sometimes
limited also after radical surgeries. Our algorithm, instead, could
potentially be used also in cytological samples, as illustrated in
Supplementary Figure 1.
Given the rarity of this kind of lung tumours, we defined the
algorithm on a relatively low number of samples. However,
the high sensitivity and reproducibility of this new diagnostic
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Figure 2. (A and B) Results of RQ-PCR for CEACAM1 and GC on 12 lung carcinoid samples. Results are shown on samples with the original
diagnosis (A) and following the final evaluation (B). Grey bars represent results for CEACAM1 and black bars for GC. Samples have been numbered
according to Table 1. Circled numbers represent typical carcinoids and plain numbers stand for atypical. Samples have been numbered according
to Table 1. Misdiagnosed cases are marked with grey arrowheads. Asterisks indicate samples with out-of-scale fold changes: values were 18266.71
for sample #2, 4042.27 for sample #4, and 4510.04 for sample #10. Please note: the lack of uniformity in the scales of the two charts reporting
CEACAM1 and GC expression is due to the strong difference in the levels detected for the two genes.
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Figure 3. Representative examples of CEACAM and GC immunostaining. Immunoreactivity was rendered semiquantitatively on a scale from
negative to 3þ . Tumours were considered as negative if staining was completely absent; 1þ cases showed weak reactivity, 2þ moderate, and
3þ cases showed strong reactivity. The percentage of positive cells was taken into account and registered in each case.
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algorithm strongly support a further validation effort on a wider
sample size, to investigate whether this potential tool could become
a part of the routine diagnostic procedure.
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Table 2. Definition of a new diagnostic algorithm
Marker Typical carcinoid Atypical carcinoid
CEACAM40 — X
CEACAM¼ 0 X X
GCp20 X —
20oGCo40 (1þ ) X —
GC420 (2þ , 3þ ) — X
Abbreviations: AC¼ atypical carcinoid; TC¼ atypical carcinoid. Tumours showing CEACAM1
expression are classified as AC. Samples without detectable immunostaining are further
analysed with GC. When GC levels are scored below 20% or included between 20% and
40% with a low intensity (1þ ), the tumour is classified as TC. Finally, tumours with GC levels
above 20% and showing medium or high intensity (2þ , 3þ ) are classified as AC.
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